Shares of Sudeep Pharma came under pressure on Monday, December 22, 2025, following the announcement of its financial results for the September quarter (Q2 FY26). The stock declined as much as 6.03% during intraday trade to ₹644.90. At around 9:25 am, the shares were trading nearly 4% lower at ₹658.90, while broader market indices remained in positive territory.
Q2 FY26 Financial Performance
The company reported a moderation in profitability during the quarter, despite an increase in revenue.
- Net Profit: Declined 4% year-on-year to ₹46.8 crore in Q2 FY26, compared with ₹48.7 crore in Q2 FY25
- Revenue: Increased to ₹162.7 crore from ₹148.8 crore in the corresponding quarter last year
- EBITDA: Largely flat at ₹65.6 crore versus ₹65.3 crore in Q2 FY25
- EBITDA Margin: Reduced to 38% from 43.4% in the year-ago period
- Earnings Per Share (EPS): Decreased to ₹4.20 from ₹4.49
Company Overview
Established in 1989, Sudeep Pharma operates in the segment of mineral-based excipients, speciality nutrition ingredients, and food-grade minerals. The company supplies derivatives of calcium, iron, magnesium, and zinc to pharmaceutical, nutraceutical, and food companies across more than 100 countries.
IPO Background
Sudeep Pharma was listed on the stock exchanges on November 28, 2025. The shares debuted at a premium of over 23% to the IPO issue price of ₹593.
Summary
Sudeep Pharma reported a year-on-year decline in net profit and margins for Q2 FY26, even as revenue recorded growth. The company’s EBITDA remained largely unchanged, while EPS declined. The stock reacted negatively following the earnings announcement.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.